Cover Image

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

Saved in:

Bibliographic Details
Main Authors:	Luigi Gargiulo (Author), Luciano Ibba (Author), Matteo Bianco (Author), Sara Di Giulio (Author), Alfano Alfano (Author), Ruggero Cascio Ingurgio (Author), Paola Facheris (Author), Chiara Perugini (Author), Mario Valenti (Author), Antonio Costanzo (Author), Alessandra Narcisi (Author)
Format:	Book
Published:	Taylor & Francis Group, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience
by: Luigi Gargiulo, et al.
Published: (2023)

Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients
by: Francesco Piscazzi, et al.
Published: (2023)

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study
by: Luciano Ibba, et al.
Published: (2023)

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
by: Luigi Gargiulo, et al.
Published: (2023)

Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review
by: Ibba L, et al.
Published: (2024)

Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study
by: Luigi Gargiulo, et al.
Published: (2023)

Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study
by: Luciano Ibba, et al.
Published: (2024)

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers
by: Diego Orsini, et al.
Published: (2023)

Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience
by: Luigi Gargiulo, et al.
Published: (2023)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2023)

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks
by: Luciano Ibba, et al.
Published: (2023)

Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience
by: Gioele Ghezzi, et al.
Published: (2024)

Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study
by: Luciano Ibba, et al.
Published: (2023)

Long-term management of pediatric psoriasis with ixekizumab: a case report
by: Diego Orsini, et al.
Published: (2023)

Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report
by: Mario Valenti, et al.
Published: (2024)

Risankizumab for the Treatment of Palmoplantar Pustular Psoriasis: A Report of Two Cases
by: Luigi Gargiulo, et al.
Published: (2023)

Real-Life Safety and Effectiveness of Dupilumab in Patients With Concomitant Malignancies: A Case Series
by: Luigi Gargiulo, et al.
Published: (2023)

Retreatment with upadacitinib in atopic dermatitis: experience in clinical practice
by: S. Martínez-Fernández, et al.
Published: (2023)

Anti-IL17 and anti-IL23 biologic drugs for genital psoriasis: a single-center retrospective comparative study
by: Andrea Cortese, et al.
Published: (2023)

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab
by: Luigi Gargiulo, et al.
Published: (2023)

A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis-IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024)

Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment
by: Mario Valenti, et al.
Published: (2024)

Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis
by: Emily Seale, MPH, et al.
Published: (2023)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024)

Atypical facial pustular folliculitis by <i>Klebsiella pneumoniae</i>: a case report
by: Mario Valenti, et al.
Published: (2023)

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study
by: Nina Magnolo, et al.
Published: (2024)

Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis)
by: Luigi Gargiulo, et al.
Published: (2024)

Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab
by: Yan Yang, et al.
Published: (2023)

Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report
by: Ting Pan, et al.
Published: (2023)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
by: Miguel Nogueira, et al.
Published: (2021)

Early itch relief with upadacitinib predicts later skin clearance in Atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024)

Consideration of treatment goals and termination algorithm for adolescent atopic dermatitis using upadacitinib
by: Takeshi Koga, et al.
Published: (2024)

Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus
by: Luigi Gargiulo, et al.
Published: (2024)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021)

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis
by: L. Mastorino, et al.
Published: (2023)

More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
by: Andrew Blauvelt, et al.
Published: (2024)

Effectiveness of upadacitinib in Japanese patients with prurigo‐type atopic dermatitis: Four cases report
by: Keiji Kosaka, et al.
Published: (2023)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
by: Yuliya Lytvyn, et al.
Published: (2022)

New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series
by: Luigi Gargiulo, et al.
Published: (2023)

Consecutive Use of the 52 mg Levonorgestrel-releasing Intrauterine System: Variations in Bleeding Patterns
by: Barbara Zantut Wittmann, et al.
Published: (2020)